June 26 (Reuters) - Semnur Pharmaceuticals Inc:
* trial also showed that adverse events were comparable between two treatments
* Semnur pharmaceuticals inc announces successful phase 1 / 2 trial in patients with radicular pain for its lead product, SP-102
* trial was conducted in patients with radicular pain, achieved its primary pharmacokinetic endpoint
* announced successful phase 1 / 2 pharmacokinetic bridging trial of lead product SP-102 Source text for Eikon: Further company coverage:
Our Standards: The Thomson Reuters Trust Principles.